Diabetes drug of Glaxo will be subjected to a panel vote of US advisers

Diabetes drug of Glaxo will be subjected to a panel vote of US advisersOn Wednesday a diabetes drug’s fate will be decided when it will be subjected to the votes of Us advisers on if the drug which is widely used poses too much of heart attack risk to get sold in the market.This drug is fromGlaxoSmithKline Plc (GSK.L)  

Records reveal Galxo’s Avandia is a potential killer

Records reveal Galxo’s Avandia is a potential killerA special hearing by the US regulators could decide the fate of the once popular drug of Glaxo, Avandia which was claimed to change the lives of people who suffer from diabetes being accused as a potential killer now.

European Agency To Re-test Safety Of GSK's Avandia

European Agency To Re-test Safety Of GSK's AvandiaThe European Medicines Agency announced on Friday that it will initiate reviewing the safety associated with the diabetes drug, Avandia after research prompted that it is related to a boosted risk of heart issues, strokes and deaths in older adults.

The Agency posted that the review will be conducted by its Committee for Medicinal Products for Human Use, when it meets from July 19 to July 22.

Partner HGSI Files Benlysta For US Approval: GSK

GlaxoSmithKlineFirst potentially new treatment in decades for the hard-to-treat autoimmune disease lupus might be on the shelves soon as GlaxoSmithKline Plc (GSK) on Thursday said partner Human Genome Sciences Inc. (HGSI) has applied for U. S. regulatory approval for their jointly-developed drug Benlysta.

Rotarix vaccine banned by UAE

GlaxoSmithKline-Rotarix-VaccineOn Wednesday, Dr Amin Al-Amiri, CEO for Medical Practice and Licensing at the Ministry announced the UAE Ministry of Health has taken the decision to suspend utilization of GlaxoSmithKline's Rotarix vaccine for some time. The vaccine was found to be impure with extraneous viral DNA bits from the porcine circovirus 1 (or PVC1).

GSK Research Jobs Shift Away from Anti-Depressants

Hundreds of research and development jobs in the UK will shift to GlaxoSmithKline as Europe’s biggest pharmaceuticals company stops researching anti-depressant medicines a pivotal part of its historical neuroscience activity, to save £500m a year in costs by 2012. Andrew Witty , chief executive revealed about an 18 per cent rise in full-year pre-tax profits to £7.9bn on sales up 16 per cent to £28.4bn in the 12 months to December 31.